A listed company developing circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology is ‘transitioning’ its CEO and CFO out of the business.

ANGLE plc said chief exec Andrew Newland and finance chief Ian Griffiths – neither of whom is on the company’s board – will have their contractual entitlements honoured over the next 12 months.

Chairman Dr Jan Groen has moved into an executive role to lead the company as it pursues a revised strategy, focused on tight cost control, accelerated commercial progress and a clear plan towards becoming a sustainable business.

Dr Groen has over 25 years of experience in the commercialisation of clinical and personalised oncology diagnostics, and has led the turnaround of several companies.

The company has a cash runway into Q1 2026 and will need to raise funds in the coming months. It is also proposing to change its name to CelLBxHealth plc.